Agilent

Patients with PD-L1-expressing gastric or gastroesophageal junction tumors can now be identified for potential treatment with Keytruda using Agilent's assay.

The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.

The CDC received clearance for a number of influenza panels and kits. Agilent's assay for postnatal CNV detection, and Abbott's hematocrit test were also cleared. 

The test is now CE marked for use in identifying patients with urothelial cancer who are most likely to benefit from Opdivo therapy.

The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio. 

The companies will work together to develop a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.

The test can now be used to identify patients with squamous cell carcinoma of the head and neck who are likely to benefit from Opdivo therapy.